Let's Talk Quality

← Let's Talk Quality7 Jul · 34 min

How Quality Stopped Being Black and White, with Tim Mitchell

How Quality Stopped Being Black and White, with Tim Mitchell7 Jul34 min

Forty seven years in quality, and Tim Mitchell says the job he started is nothing like the one he does today.

Tim Mitchell on how quality stopped being black and white

In today's episode I was joined by Tim Mitchell, Vice President of Quality at Aktis Oncology, a radiopharmaceutical company in Boston developing treatments across several types of cancer. I really wanted to speak to Tim because very few people have watched quality evolve the way he has. He started in 1980, when the GMP regulations were barely a year and a half old and a quality assurance function did not really exist yet.

Tim's story begins in a loud, industrial antibiotic fermentation plant, monitoring sixty to ninety thousand gallon fermenters that ran into the ground. His father worked in the neighbouring department at Eli Lilly, and an internship near his hometown turned into fourteen years at Lilly and a career that carried him from big pharma through to the start-up world he works in now. Along the way he moved from manufacturing into a validation team, without knowing what validation even was, and found that quality suited him.

What comes through most is his view of the role itself. Tim does not see quality as a police force. He sees it as a collaborative partner to the rest of the business, a role that demands technical depth, patience and judgement. He talks openly about how the work has moved from black and white rule-following to something far more gray, especially in early-stage biotech where the science is moving faster than the rulebook.

We talk about the following:

How the quality function grew from a paperwork desk job into a value-adding partnershipWhy some of the best quality people come from manufacturing backgroundsThe case for learning proper GMP systems in big pharma before joining a start-upWhat good mentoring actually looks like, and why annual reviews are not enoughHow the relationship between the FDA and biotech is becoming genuinely collaborative

Tim Mitchell is a thoughtful, pragmatic quality leader who understands how to balance compliance, collaboration and business reality in complex development environments. If you are a quality professional working in an early-stage biotech and trying to build the right systems with limited resources, then this episode is for you. Thank you Tim for sharing your incredible journey. Hope everyone enjoys the show.

WHO THIS EPISODE IS FOR

Quality professionals moving from big pharma into a clinical-stage biotechManagers building or scaling a quality management system from scratchManufacturing and technical operations people considering a move into qualityVPs and Directors of Quality thinking about how they mentor their teamsAnyone early in their quality career trying to understand where the role is heading

Timestamps:

(00:00) Introduction to Tim Mitchell and His Journey